This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Next Week's Game Plan (Final)

Stocks in this article: ISPHAGNTEVA

Lucrative Prospects

For "Speculation Friday," Cramer recommended Inspire Pharmaceuticals (ISPH), the last in his series of biotech companies with blockbuster drug potential.

Cramer said investors have two ways to win with Inspire. First, he said the company is a likely takeover target by Allergan (AGN). Inspire is already in a close partnership with Allergan for two drugs to treat dry eyes and pink eye. Cramer said it makes sense for Allergan, a much larger company, just to buy all of Inspire, rather than continue licensing it's products.

Even more attractive however is Inspire's pulmonary business and its treatment for cystic fibrosis, which is currently in phase III testing. Cramer said Inspire's treatment is unlike any other, and just received orphan status from the government, meaning it will have no competition. Cramer said the drug, due for approval in the second half of 2011, could be a $300 million to $500 million opportunity.

Cramer said with $106 million in cash on the books, Inspire is not going belly up anytime soon. Cramer said he'd be a buyer of Inspire with so many lucrative prospects.

Going With Teva

Continuing his biotech theme, Cramer honed in on muscular sclerosis, a disease affecting 350,000 people in the U.S., and the companies working towards a cure.

Cramer said MS drugs currently weigh in at $10 billion annually, with estimates upwards of $15 billion over the next 10 years. Cramer said while Biogen Idec (BIIB) remains a favorite in this space, he'd be a seller of the company, as increased competition is on the horizon.

Cramer explained that new treatments are on the way, including ones that come in pill form, as opposed to an injection, and ones that offer fewer serious side effects. He said the extent to which these new drugs will affect Biogen's business have not been factored into the stock.

But Cramer said he is a fan of Teva Pharmacueticals (TEVA), the world's largest generic drug maker, which also happens to have a great branded drug business, one quarter of which is dedicated to MS. Teva is also a stock which he also owns for his Action Alerts PLUS portfolio.

Cramer said Teva is the smart, safe way to play MS, as Teva's MS drug will not be affected by new competition. He said the stock took a big hit back in July on patent expiration fears, but those fears were unfounded, as the company's patents remain in good shape through 2014.

Trading at just 10 times earnings, Cramer said Teva is a terrific risk reward, especially given its projected 14% growth rate and healthy drug pipeline.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,764.89 +86.99 0.52%
S&P 500 1,959.10 +8.28 0.42%
NASDAQ 4,470.9180 +18.1260 0.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs